Background: The Patient Registry of Intrathecal Ziconotide Management (PRIZM) evaluated long-term effectiveness, safety, and tolerability of intrathecal ziconotide treatment in clinical practice. Methods: Patient Registry of Intrathecal Ziconotide Management was an open-label, long-term, multicenter, observational study of adult patients with severe chronic pain. This interim analysis (data through July 10, 2015) of ziconotide as the first vs. not first intrathecal agent in pump included change from baseline in the Numeric Pain Rating Scale (NPRS; primary efficacy measure) and Patient Global Impression of Change (PGIC) scores. Results: Enrollment closed at 93 patients; data collection was ongoing at the time of this interim analysis. Fifty-one patients (54.8%) received ziconotide as the first agent in pump (FIP+), whereas 42 (45.2%) did not (FIPÀ). Mean (SD) baseline NPRS scores were 7.4 (1.9) and 7.9 (1.6) in FIP+ and FIPÀ patients, respectively. Mean (SEM) percentage changes in NPRS scores were À29.4% (5.5%) in FIP+ patients (n = 26) and +6.4% (7.7%) in FIPÀ patients (n = 17) at month 6 and À34.4% (9.1%) in FIP+ patients (n = 14) and À3.4% (10.2%) in FIPÀ patients (n = 9) at month 12. Improvement from baseline, measured by PGIC score, was reported in 69.2% of FIP+ (n = 26) and 35.7% of FIPÀ (n = 14) patients at month 6 and 85.7% of FIP+ (n = 7) and 71.4% of FIPÀ (n = 7) patients at month 12. The most common adverse events (≥ 10% of patients overall as of the data cut) were nausea (19.6% vs. 7.1% of FIP+ vs. FIPÀ patients, respectively), confusional state (9.8% vs. 11.9%), and dizziness (13.7% vs. 7.1%). Conclusions: Greater improvements in efficacy outcomes were observed when ziconotide was initiated as first-line intrathecal therapy vs. not first intrathecal agent in pump.
INTRODUCTION
Ziconotide is an intrathecally delivered, nonopioid analgesic agent approved in the United States for the management of severe chronic pain in adult patients for whom intrathecal (IT) therapy is warranted and who are intolerant of or refractory to other treatments, such as systemic analgesics, adjunctive therapies, or IT morphine. 1, 2 Ziconotide is a selective and reversible N-type calcium channel blocker. 3 Preclinical studies suggest that ziconotide prevents calcium entry into presynaptic nerve terminals, which inhibits the presynaptic release of neurotransmitters and neuropeptides that mediate pain, resulting in antinociception. [3] [4] [5] The efficacy of IT ziconotide for the treatment of severe chronic pain was established in randomized, double-blind, placebo-controlled trials. [6] [7] [8] However, few studies have been conducted in clinical practice settings to evaluate the effectiveness of IT ziconotide therapy. [9] [10] [11] The Patient Registry of Intrathecal Ziconotide Management (PRIZM) study was designed to assess long-term effectiveness (via patient-reported outcomes), safety, and tolerability associated with IT ziconotide therapy in the management of patients with severe chronic pain in current clinical practice. The objective of this interim analysis of PRIZM data was to evaluate these measures in patients who received ziconotide as the first vs. not first agent in pump.
METHODS

Study Design
Patient Registry of Intrathecal Ziconotide Management was a prospective, open-label, long-term, multicenter, observational study (registry). The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practices guidelines, the ethical principles of the Declaration of Helsinki, and the provisions of the U.S. Health Insurance Portability and Accountability Act of 1996. Study procedures were approved by an institutional review board or independent ethics committee at each site, and all patients provided written informed consent before study enrollment.
Eligible patients were adults (≥ 18 years old) with severe chronic pain who met ziconotide prescribing information criteria and had a life expectancy > 6 months (as determined by the physician). 2 Patients were required to initiate IT ziconotide as the sole agent in a new or previously implanted pump. Addition of other IT agents (combination IT therapy) was permitted during treatment at the discretion of the investigator. Patients already receiving IT therapy were permitted to enroll in PRIZM after weaning/switching from another IT regimen. The process for weaning previous IT medications was not mandated by a protocol. Processes for tapering and discontinuation of previous IT medications were based on the clinical practice of the individual investigators. There were no restrictions on concomitant non-IT treatments; oral opioids and other systemic medications were permitted during the tapering period. Patients with previous or current ziconotide use could be enrolled into the study after a > 30-day lapse or washout of ziconotide. Patients were excluded from the study if they had a pre-existing history of psychosis; an infection at the microinjection site; uncontrolled bleeding diathesis; or known spinal canal obstruction that could impair flow of cerebrospinal fluid; or were taking a concomitant medication or had a medical condition that would render IT ziconotide administration hazardous in the opinion of the investigator.
Ziconotide was administered via the Medtronic SynchroMed II Infusion System, which allowed for an initial dose as low as 1.2 lg/day using the undiluted 25 lg/mL ziconotide formulation. The IT pump reservoir was to be rinsed with ziconotide before the initial fill, as directed in the manufacturer's manual. 12 According to the prescribing information, IT ziconotide should be initiated at no more than 2.4 lg/day (0.1 lg/hour) and titrated upward by ≤ 2.4 lg/day (0.1 lg/hour) at a frequency of no more than 2 to 3 times per week based on analgesic response and adverse events. 2 All treatment decisions and clinical assessments were made at the discretion of the treating clinician. The frequency of clinic visits was determined by individual physician practices or the need to titrate the dose or refill the pump with ziconotide. The primary efficacy outcome was "average pain for the past 24 hours" as rated by patients on an 11-point Numeric Pain Rating Scale (NPRS; ranging from 0 [no pain] to 10 [pain as bad as the patient can imagine]) at week 12; the NPRS was assessed at every clinic visit. Treatment response was defined as a ≥ 30% reduction from the baseline NPRS score. The Patient Global Impression of Change (PGIC; a 7-point ordered categories of patient's rating of overall improvement: "very much better," "much better," slightly better," "no change," "slightly worse," "much worse," and "very much worse"), a secondary efficacy outcome, was evaluated at month 3 and every 3 months thereafter. Improvement in overall status, as measured by the PGIC, was defined as a response of "very much better," "much better," or "slightly better." Safety assessment for adverse events and vital signs was performed at every clinic visit. Enrolled patients were followed for up to 18 months (as long as they continued to receive IT ziconotide as the sole agent or in combination with other IT agents). Although PRIZM enrollment has closed, data collection was ongoing at the time of this interim analysis.
Interim Subset Analysis
This interim analysis reports efficacy results through month 12 for the all treated population, which was defined as patients who were treated with IT ziconotide and for whom data were entered into the PRIZM database as of July 10, 2015 (regardless of data availability for all time points). We evaluated IT ziconotide therapy for patients by ziconotide as their first vs. not first agent in pump status. No protocolspecified hypothesis was tested in this nonrandomized, observational study; data were summarized using descriptive statistics and no inferential statistical tests were performed. All NPRS and PGIC data shown were observed; no effectiveness data have been imputed. Because a clinic visit was required to modify ziconotide dosing, the dose for active patients who did not have a visit at a nominal time point was carried forward from the dose programmed at the previous clinic visit.
RESULTS
Patients
This interim analysis included 93 patients enrolled at 23 centers in the United States from September 5, 2013 through June 30, 2015 (when enrollment closed), with a data cut-off of July 10, 2015. The PRIZM patient population was primarily female (61.3%) and White (96.8%), with an average age of 56.3 years and chronic pain of nonmalignant etiology (95.7%). Almost all patients (93.5%) had received treatment with oral opioids previously, and most patients had also received ≥ 1 other systemic pharmacologic treatment. In addition, most patients in the study (81.7%) had previously received epidural injections or infusions. The treating physician's primary reason for selecting IT ziconotide therapy was "inadequate pain relief with systemic medications or epidural injections and infusions" (48.4% of patients), "inadequate pain relief with other intrathecal medications" (31.2%), "inadequate pain relief with nonpharmacologic interventions" (14.0%), "safety concerns with other intrathecal medications" (4.3%), or "tolerability issues with systemic medications" (2.2%).
Demographic and baseline characteristics of the overall population are presented in Table 1 . Fifty-one patients (54.8%) received ziconotide as first agent in pump vs. 42 patients (45.2%) as not first in pump. Pain duration was longer in patients who had received previous therapy with other IT agents. Previous IT medications included morphine (32.3% of patients), hydromorphone (22.6%), bupivacaine (19.4%), fentanyl (16.1%), clonidine (14.0%), baclofen (7.5%), and sufentanil (1.1%). The most common prespecified primary diagnoses (≥ 5% of patients) in patients with ziconotide as the first agent in pump were failed back surgery syndrome (16.7%), central pain syndrome (10.4%), complex regional pain syndrome (8.3%), low back pain (8.3%), and diabetic neuropathy (6.3%). In patients with ziconotide not first in pump, the most common diagnoses were failed back surgery syndrome (41.5%), low back pain (29.3%), and cancer pain (7.3%). Primary pain etiology that was not one of the prespecified categories was reported by 47.9% and 14.6% of patients with ziconotide as the first vs. not first agent in pump, respectively.
A trial of ziconotide was performed in 90.2% of patients for whom ziconotide was first agent in pump and in 47.6% of patients for whom ziconotide was not first agent in pump; bolus injections were used for trialing in > 90% of patients. The mean (SD) initial ziconotide dose was similar in patients with ziconotide as first vs. not first agent in pump (1.6 [1.1] vs. 1.7 [1.2] lg/day, respectively). At the time of this interim analysis, 35 patients with ziconotide as first agent in pump and 26 patients with ziconotide as not first agent in pump had been enrolled for ≥ 12 months; 54.3% (19/ 35) and 42.3% (11/26) of patients, respectively, were still active in the study, and 57.9% (11/19) and 54.5% (6/11) of these patients, respectively, remained on ziconotide monotherapy through month 12.
For patients with NPRS assessments at the corresponding visits, the mean (SD) ziconotide dose in the overall patient population was 3.2 (2.9) lg/day at week 12 (n = 59), 3.0 (2.3) lg/day at month 6 (n = 46), 2.4 (1.9) lg/day at month 9 (n = 30), and 1.9 (1.5) lg/day at month 12 (n = 21); mean (SD) dose for patients with ziconotide as first vs. not first in pump was 3.2 (3.3) lg/ day (n = 34) vs. 3.1 (2.3) lg/day (n = 25) at week 12, 2.9 (2.2) lg/day (n = 28) vs. 3.1 (2.5) lg/day (n = 18) at month 6, 1.8 (1.8) lg/day (n = 18) vs. 3.4 (1.7) lg/ day (n = 12) at month 9, and 1.5 (1.2) lg/day (n = 14) vs. 2.7 (1.7) lg/day (n = 7) at month 12.
Efficacy
In the overall patient population, mean (SEM) percentage change from baseline in NPRS score was À10.4% (3.5) at week 12 (n = 61), À15.2% (5.2) at month 6 (n = 43), À16.2% (7.4) at month 9 (n = 30), and À22.3% (7.4) at month 12 (n = 23). For patients with ziconotide as first vs. not first in pump, mean (SEM) percentage changes in NPRS scores are shown in Figure 1 . Mean (SEM) percentage change was À16.0% (4.2) in patients with ziconotide as first agent in pump (n = 35) and À2.8% (5.8) in patients with ziconotide not first in pump (n = 26) at week 12, À29.4% (5.5) in patients with ziconotide as first agent in pump (n = 26) and +6.4% (7.7) in patients with ziconotide not first in pump (n = 17) at month 6, À22.3% (7.0) in patients with ziconotide as first agent in pump (n = 18) and À6.9% (15.2) in patients with ziconotide not first in pump (n = 12) at month 9, and À34.4% (9.1) in patients with ziconotide first in pump (n = 14) and À3.4% (10.2) in patients with ziconotide not first in pump (n = 9) at month 12.
Treatment response (defined as ≥ 30% reduction in NPRS score from baseline) rate in the overall population was 16.4% (10/61) at week 12, 30.2% (13/43) at month 6, 36.7% (11/30) at month 9, and 34.8% (8/23) at month 12. Treatment response was observed in a greater proportion of patients with ziconotide as first agent in pump vs. not first agent in pump at most time points (Figure 2 ). Twenty percent (7/35) of patients with ziconotide first in pump and 11.5% of patients (3/26) with ziconotide not first in pump were classified as treatment responders at week 12; 46.2% (12/26) and 5.9% (1/17) of patients, respectively, at month 6; 38.9% (7/18) and 33.3% (4/12) of patients, respectively, at month 9; and 50.0% (7/14) and 11.1% (1/9) of patients, respectively, at month 12, were classified as responders.
Among patients enrolled for ≥ 12 months who had NPRS scores at baseline and months 3, 6, 9, and 12 data collection time points, mean (SEM) percentage change in NPRS scores for patients with ziconotide first in pump (n = 13) and not first in pump (n = 8) were À19.2% (7.9) and À12.2% (7.8) at month 3, À30.8% (7.2) and À4.3% (4.0) at month 6, À22.8% (9.3) and À22.3% (7.4) at month 9, and À32.7% (9.7) and À5.4% (11.4) at month 12, respectively.
In the overall patient population, 64.5% (40/62), 57.5% (23/40), 65.2% (15/23), and 78.6% (11/14) of patients at months 3, 6, 9, and 12, respectively, reported improvement in overall status since the beginning of the study on the PGIC. Improvement in overall status since the beginning of the study was reported by 73.7% of patients (28/38) with ziconotide first in pump and 50.0% of patients (12/24) with ziconotide not first in pump at month 3; 69.2% (18/26) and 35.7% (5/14) of patients, respectively, at month 6; 75.0% (12/16) and 42.9% (3/7) of patients, respectively, at month 9; and 85.7% (6/7) and 71.4% (5/7) of patients, respectively, at month 12 ( Figure 3 ).
Safety
Adverse events, as of the interim data cut-off date, were reported by 71.0% of patients overall: 80.4% of patients with ziconotide first in pump and 59.5% of patients with ziconotide not first in pump ( Table 2 ). The most common adverse events overall (≥ 10% of patients) were nausea (14.0%), confusional state (10.8%), and dizziness (10.8%). Adverse events led to study discontinuation in 16.1% of patients overall: 23.5% of patients with ziconotide first in pump and 7.1% of patients with ziconotide not first in pump. Serious adverse events were experienced by 20 patients (21.5%) overall: 10 patients (19.6%) with ziconotide as the first agent in pump and 10 patients (23.8%) with ziconotide as not first agent in pump. Serious adverse events in patients with ziconotide as the first agent in pump were suicidal ideation (n = 2), depression, device inversion, dyspnea, grief reaction, hypertension, implant site effusion, intestinal obstruction, postoperative wound infection, psychotic disorder, respiratory distress, and urinary tract infection (n = 1 patient each). Serious adverse events in patients with ziconotide as not first agent in pump were mental status changes (n = 2), asthenia, Clostridium difficile colitis, cerebral hematoma, cerebral hemorrhage, "cerebral pressure" (not coded to a Medical Dictionary for Regulatory Activities [MedDRA] preferred term), chronic obstructive pulmonary disease, constipation, encephalopathy, exostosis, fall, hypokalemia, lower abdominal pain, "medical instability due to respiratory insufficiency and edema" (not coded to a MedDRA preferred term), paraplegia, and volvulus (n = 1 patient each). One patient died (cardiopulmonary arrest); this death was considered by the study investigator to be unrelated to ziconotide.
DISCUSSION
Patient Registry of Intrathecal Ziconotide Management was a multicenter, observational study of the long-term effectiveness, safety, and tolerability of IT ziconotide treatment in clinical practice settings. This interim analysis of PRIZM data through month 12 found that IT ziconotide provided clinically meaningful pain reduction (i.e, ≥ 30% decrease in NPRS score) in more than 30% of patients at most assessment time points. This treatment response was largely driven by patients for Month 12 (n = 7)
Month 12 (n = 7) whom ziconotide was initiated as first-line IT monotherapy vs. not first IT agent in pump. The adverse event profile of IT ziconotide observed in this analysis was consistent with that in a previous randomized, controlled trial that used a slow titration protocol similar to the current dosing recommendations and as previously reported in the literature.
2,7
The recommended dosing of IT ziconotide (starting dose of 0.5 to 2.4 lg/day with slow, incremental dose titration based on patient response 2, 13 ) was developed to provide sufficient pain reduction while lessening the adverse effects observed in early studies that used higher starting doses and rapid titration. 6, 8 The mean initial ziconotide dose in this PRIZM analysis was 1.6 lg/day titrated to a mean of 3.2 lg/day at week 12, 3.0 lg/day at month 6, 2.4 lg/day at month 9, and 1.9 lg/day at month 12, which is consistent with current dosing recommendations. 2, 13 This suggests that low doses at the start of ziconotide infusion and slow upward titration may allow patients to achieve an analgesic effect while improving tolerability. The randomized, placebo-controlled studies that supported the U.S. Food and Drug Administration approval of IT ziconotide employed a treatment phase that lasted from 10 days to 3 weeks. [6] [7] [8] By contrast, the PRIZM study followed patients for an extended duration (up to 18 months), allowing evaluation of longterm IT ziconotide therapy. PRIZM showed a persistent treatment response through month 12 in an analysis of 21 patients with NPRS scores at all relevant time points. Findings from PRIZM are supported by an Italian observational study (N = 104), which included a separate analysis of 45 patients who remained on IT ziconotide for > 6 months; the study reported a sustained analgesic effect in this patient group. 10 Notably, 57% of patients still active in PRIZM at month 12 and 69% of patients who remained in the Italian registry study longer than 6 months were receiving IT ziconotide monotherapy. 10 This suggests that sustained pain reduction may be obtained with long-term treatment using IT ziconotide monotherapy, with the addition of adjunctive IT agents in some patients, as needed, to optimize efficacy. Results from 2 previous observational studies suggest that ziconotide may also be effective as part of combination IT regimens with IT morphine and other agents. 9, 11 In this PRIZM analysis, treatment response was greater when ziconotide was initiated as first-line IT therapy. This is consistent with the Polyanalgesic Consensus Conference guideline recommendations of ziconotide use as first-line IT therapy for patients with neuropathic or nociceptive pain. 13 Notably, more than 50% of patients active at month 12 remained on ziconotide monotherapy. One factor potentially contributing to greater treatment response when ziconotide was initiated as first-line IT monotherapy vs. not first agent in pump is that patients who have failed to achieve adequate analgesia with prior IT therapy may have pain that is more refractory and therefore more difficult to treat. In this analysis, mean pain duration was longer in patients for whom ziconotide was not first agent in pump, although mean pain severity was similar to firstin-pump patients. In addition, primary diagnoses differed between the 2 groups, which may have resulted in dissimilar treatment response. While the adverse event profile in this PRIZM analysis was generally consistent with that reported in the ziconotide prescribing information, there were some differences between patients with ziconotide as the first vs. not first agent in pump, which may be related to differences in diagnosis and/or treatment history. There are few studies comparing ziconotide as first-line IT monotherapy to ziconotide as not first agent in pump. A retrospective review of patients treated with ziconotide in a clinical practice setting (n = 15) found that 53% had good treatment outcomes with ziconotide as first-line IT monotherapy using a low-dose/slow-titration strategy; however, this study did not evaluate outcomes in patients exposed to other agents in the pump prior to ziconotide.
14 Additionally, in the Italian registry, although 53% (55/104) of patients received ziconotide as first-line IT therapy (the other 47% had been previously treated with IT morphine), results were not reported separately for patients with ziconotide as the first vs. not first agent in pump. 10 Some limitations of the PRIZM study, such as the open-label administration of study medication and lack of a placebo control group, are typical of observational studies. In addition, the sample size at later time points in the analyses were relatively small, which may limit the generalizability of the results. Because this analysis was based on patients with available data, the findings do not take into account treatment discontinuation due to lack of efficacy or adverse events.
The PRIZM registry was a long-term evaluation of IT ziconotide; data collection was ongoing at the time of this interim analysis, and patients were to be followed up to 18 months (as long as they continued to receive IT ziconotide). This interim PRIZM analysis found that IT ziconotide provided clinically meaningful pain relief to a subset of enrolled patients at each assessment through month 12. Improvement on efficacy outcomes was greater when ziconotide was initiated as first-line IT therapy vs. not first IT agent in pump. The adverse event profile was consistent with ziconotide prescribing information. The final analysis of the PRIZM study will provide additional information on the long-term effectiveness and safety of IT ziconotide in the management of chronic pain in clinical practice.
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